Literature DB >> 22202649

Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1.

Ivan A Borbon1, Zach Hillman, Ernesto Duran, Pawel R Kiela, Sally A Frautschy, Robert P Erickson.   

Abstract

In order to determine the efficacy of curcumin in ameliorating symptoms of neurodegeneration in the mouse model of Niemann-Pick C1, a variety of formulations and dosages of curcumin, one comparable to one previously reported as efficacious, were provided orally to Npc1(-/-)mice. Plasma levels of curcumin, survival, tests of motor performance, and memory (in some cases) were performed. We found variable, but mild, increases in survival (1.5% to 18%). The greatest increased survival occurred with the highest dose (which was unformulated) while the control for the lipidated formulation (containing phosphatidylcholine and stearic acid) had an equivalent impact and other formulations, while not significantly increased, are also not statistically different in effect from the highest dose. We conclude that curcumin is not a highly efficacious treatment for neurodegeneration in Npc1(-/-) mice. Phosphatidylcholine and stearic acid should be studied further.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202649      PMCID: PMC3466425          DOI: 10.1016/j.pbb.2011.12.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  52 in total

1.  Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats.

Authors:  Kuntal Maiti; Kakali Mukherjee; Arunava Gantait; Bishnu Pada Saha; Pulok K Mukherjee
Journal:  Int J Pharm       Date:  2006-09-23       Impact factor: 5.875

2.  Reduction in cholesterol absorption is enhanced by stearate-enriched plant sterol esters in hamsters.

Authors:  Heather E Rasmussen; David M Guderian; Curtis A Wray; Patrick H Dussault; Vicki L Schlegel; Timothy P Carr
Journal:  J Nutr       Date:  2006-11       Impact factor: 4.798

3.  Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.

Authors:  Hiroyuki Hanai; Takayuki Iida; Ken Takeuchi; Fumitoshi Watanabe; Yasuhiko Maruyama; Akira Andoh; Tomoyuki Tsujikawa; Yosihihide Fujiyama; Keiichi Mitsuyama; Michio Sata; Masami Yamada; Yasushi Iwaoka; Kazunari Kanke; Hideyuki Hiraishi; Kazuhisa Hirayama; Hajime Arai; Shigehito Yoshii; Masato Uchijima; Toshi Nagata; Yukio Koide
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11-13       Impact factor: 11.382

4.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model.

Authors:  M Garcia-Alloza; L A Borrelli; A Rozkalne; B T Hyman; B J Bacskai
Journal:  J Neurochem       Date:  2007-04-30       Impact factor: 5.372

5.  Tetrahydrocurcumin in plasma and urine: quantitation by high performance liquid chromatography.

Authors:  Dennis D Heath; Milagros A Pruitt; Dean E Brenner; Aynun N Begum; Sally A Frautschy; Cheryl L Rock
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2005-09-25       Impact factor: 3.205

Review 6.  Curcumin: the Indian solid gold.

Authors:  Bharat B Aggarwal; Chitra Sundaram; Nikita Malani; Haruyo Ichikawa
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

7.  p35/p25 is not essential for tau and cytoskeletal pathology or neuronal loss in Niemann-Pick type C disease.

Authors:  Janice L Hallows; Robert E Iosif; Rebecca D Biasell; Inez Vincent
Journal:  J Neurosci       Date:  2006-03-08       Impact factor: 6.167

8.  Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine.

Authors:  Timothy H Marczylo; Richard D Verschoyle; Darren N Cooke; Paolo Morazzoni; William P Steward; Andreas J Gescher
Journal:  Cancer Chemother Pharmacol       Date:  2006-10-19       Impact factor: 3.333

9.  NPC2, the protein deficient in Niemann-Pick C2 disease, consists of multiple glycoforms that bind a variety of sterols.

Authors:  Heng-Ling Liou; Sayali S Dixit; Sujuan Xu; G Stephen Tint; Ann M Stock; Peter Lobel
Journal:  J Biol Chem       Date:  2006-10-02       Impact factor: 5.157

10.  Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin.

Authors:  Milan Fiala; Philip T Liu; Araceli Espinosa-Jeffrey; Mark J Rosenthal; George Bernard; John M Ringman; James Sayre; Laura Zhang; Justin Zaghi; Sheila Dejbakhsh; Ben Chiang; James Hui; Michelle Mahanian; Anita Baghaee; Pamela Hong; John Cashman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-24       Impact factor: 11.205

View more
  9 in total

1.  Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.

Authors:  Benny Liu
Journal:  Clin Lipidol       Date:  2012-06

2.  Rescue of an in vitro neuron phenotype identified in Niemann-Pick disease, type C1 induced pluripotent stem cell-derived neurons by modulating the WNT pathway and calcium signaling.

Authors:  Anastasia G Efthymiou; Joe Steiner; William J Pavan; Stephen Wincovitch; Denise M Larson; Forbes D Porter; Mahendra S Rao; Nasir Malik
Journal:  Stem Cells Transl Med       Date:  2015-01-30       Impact factor: 6.940

Review 3.  Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia.

Authors:  Robert P Erickson
Journal:  J Appl Genet       Date:  2013-01-05       Impact factor: 3.240

4.  Relative efficacy of nicotinamide treatment of a mouse model of infantile Niemann-Pick C1 disease.

Authors:  Craig A Marshall; Ivan A Borbon; Robert P Erickson
Journal:  J Appl Genet       Date:  2016-10-25       Impact factor: 3.240

Review 5.  Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.

Authors:  Paul Helquist; Frederick R Maxfield; Norbert L Wiech; Olaf Wiest
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

Review 6.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

7.  Acidic Ca2+ stores in neurodegeneration.

Authors:  Emyr Lloyd-Evans
Journal:  Messenger (Los Angel)       Date:  2016-06-01

Review 8.  Understanding and Treating Niemann-Pick Type C Disease: Models Matter.

Authors:  Valentina Pallottini; Frank W Pfrieger
Journal:  Int J Mol Sci       Date:  2020-11-26       Impact factor: 5.923

9.  Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.

Authors:  Elena-Raluca Nicoli; Nada Al Eisa; Celine V M Cluzeau; Christopher A Wassif; James Gray; Kathryn R Burkert; David A Smith; Lauren Morris; Stephanie M Cologna; Cody J Peer; Tristan M Sissung; Constantin-Daniel Uscatu; William D Figg; William J Pavan; Charles H Vite; Forbes D Porter; Frances M Platt
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.